Merck (MRK) Gains from Sales and Divestitures (2012)
Merck (MRK) reported Gains from Sales and Divestitures of $756000.0 for Q4 2012.
Merck (MRK) Gains from Sales and Divestitures (2012) Analysis & Trends
Merck (MRK) has 1 years of Gains from Sales and Divestitures data on file, last reported at $756000.0 in Q4 2012.
- Gains from Sales and Divestitures for Q4 2012 came in at $756000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2012 was $756000.0 (changed N/A YoY), and the FY2012 annual result was $756000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures held at $756000.0 in Q4 2012 per MRK's latest filing.
- Over five years, Gains from Sales and Divestitures peaked at $756000.0 in Q4 2012 and troughed at $756000.0 in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 756,000.00 |
| Dec 31, 2012 | 756,000.00 |